Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings
TW Stadnik, C Chaskis, A Michotte… - American journal …, 2001 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: The purposes of this study were to find the role of diffusion-weighted
MR imaging in characterizing intracerebral masses and to find a correlation, if any…
MR imaging in characterizing intracerebral masses and to find a correlation, if any…
[HTML][HTML] Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
…, T Strauven, C Chaskis, P In't Veld, A Michotte… - Annals of …, 2009 - Elsevier
Background To evaluate the antitumor activity and toxicity of single-agent cetuximab in
patients with recurrent high-grade glioma (HGG) after failure of surgery, radiation therapy, and …
patients with recurrent high-grade glioma (HGG) after failure of surgery, radiation therapy, and …
Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort
…, B Bergmans, J Delbeck, J Versijpt, A Michotte… - Neurology, 2015 - AAN Enterprises
Objective: To assess the genetic contribution of TBK1, a gene implicated in amyotrophic
lateral sclerosis (ALS), frontotemporal dementia (FTD), and FTD-ALS, in Belgian FTD and ALS …
lateral sclerosis (ALS), frontotemporal dementia (FTD), and FTD-ALS, in Belgian FTD and ALS …
Imaging tutorial: differential diagnosis of bright lesions on diffusion-weighted MR images
…, C Chaskis, KL Van Rompaey, A Michotte… - Radiographics, 2003 - pubs.rsna.org
High sensitivity (94%) and specificity (100%) have been reported in the diagnosis of acute
cerebral infarction with diffusion-weighted magnetic resonance (MR) imaging. However, high …
cerebral infarction with diffusion-weighted magnetic resonance (MR) imaging. However, high …
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
…, O Tynninen, N Nupponen, A Michotte… - Journal of neuro …, 2011 - Springer
Receptor tyrosine kinase signaling causes profound neo-angiogenesis in high-grade gliomas
(HGG). The KIT, PDGFR-α, and VEGFR2 genes are frequently amplified and expressed in …
(HGG). The KIT, PDGFR-α, and VEGFR2 genes are frequently amplified and expressed in …
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations
C Chaskis, B Neyns, A Michotte, M De Ridder… - Surgical neurology, 2009 - Elsevier
BACKGROUND: Treatment of newly diagnosed GBM with postoperative RT and concomitant
TMZ followed by 6 months of TMZ maintenance therapy has been shown to significantly …
TMZ followed by 6 months of TMZ maintenance therapy has been shown to significantly …
Region-and age-specific changes in glutamate transport in the AβPP23 mouse model for Alzheimer's disease
…, PP De Deyn, A Michotte, Y Michotte… - Journal of …, 2011 - content.iospress.com
Using 8-and 18-month-old AßPP23 mice, we investigated the involvement of high-affinity
glutamate transporters (GLAST, GLT-1, EAAC1), vesicular glutamate transporters (VGLUT1-3) …
glutamate transporters (GLAST, GLT-1, EAAC1), vesicular glutamate transporters (VGLUT1-3) …
TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis
We investigated the mutation spectrum of the TANK‐Binding Kinase 1 (TBK1) gene and its
associated phenotypic spectrum by exonic resequencing of TBK1 in a cohort of 2,538 …
associated phenotypic spectrum by exonic resequencing of TBK1 in a cohort of 2,538 …
[HTML][HTML] Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical …
…, L Cras, N D'Haene, A Michotte… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Patients with recurrent glioblastoma (rGB) have a poor prognosis with a
median overall survival (OS) of 30–39 weeks in prospective clinical trials. Intravenous …
median overall survival (OS) of 30–39 weeks in prospective clinical trials. Intravenous …
Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort
…, K Peeters, JJ Martin, A Michotte… - JAMA …, 2013 - jamanetwork.com
Objective To characterize patients with frontotemporal lobar degeneration (FTLD) with a repeat
expansion mutation in the gene C9orf72, and to determine whether there are differences …
expansion mutation in the gene C9orf72, and to determine whether there are differences …